Mesenchymal stromal cells and paracrine modulation of neuroplasticity in the central nervous system

Authors

  • Sacha Krolow e Silva Specialization Course in Neuroscience, Universidade Federal de São Paulo (UNIFESP), Santos, São Paulo, Brazil; Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul, Brazil https://orcid.org/0009-0008-2525-6586
  • Iris Virgínia Rondanine Sanches Specialization Course in Neuroscience, Universidade Federal de São Paulo (UNIFESP), Santos, São Paulo, Brazil; Instituto Superior de Educação União (UNISED), São Paulo, São Paulo, Brazil https://orcid.org/0009-0003-2217-4159
  • Juliana Soares Lara de Lima Specialization Course in Neuroscience, Universidade Federal de São Paulo (UNIFESP), Santos, São Paulo, Brazil; Graduate Program in Neurology/Neuroscience, Universidade Federal de São Paulo (UNIFESP), São Paulo, São Paulo, Brazil https://orcid.org/0009-0009-9683-9313
  • Luciana Le Sueur-Maluf Department of Biosciences, Universidade Federal de São Paulo (UNIFESP), Rua Silva Jardim, 133/136, Vila Mathias, Santos, São Paulo 11015-020, Brazil; E-mail: luciana.maluf@unifesp.br https://orcid.org/0000-0002-7274-459X

DOI:

https://doi.org/10.17179/excli2026-9599

Keywords:

mesenchymal stromal cells, extracellular vesicles, paracrine signaling, neuroplasticity, glymphatic system, central nervous system disorders

Abstract

Mesenchymal stromal cells (MSCs) have been widely investigated in regenerative medicine because of their immunomodulatory, anti-inflammatory, and reparative properties. Current evidence indicates that many of their effects are mediated by paracrine and intercellular mechanisms rather than sustained engraftment or direct neural replacement. This narrative review synthesizes how MSCs and MSC-derived extracellular vesicles (MSC-EVs) may modulate neuroplasticity in the central nervous system (CNS). MSC-mediated effects include trophic and immunomodulatory signaling, mitochondrial transfer via tunneling nanotubes (TNTs), efferocytosis of apoptotic MSCs by host phagocytes, blood-brain barrier stabilization, and secondary modulation of glymphatic and interstitial fluid clearance. MSC-EVs additionally deliver proteins, lipids, microRNAs, and long non-coding RNAs that regulate inflammatory and reparative gene-expression programs through well-supported post-transcriptional and emerging epigenetic mechanisms. These processes may promote neurite remodeling, angiogenesis, mitochondrial recovery, and attenuation of neuroinflammation, and may support the clearance of neurotoxic proteins. The evidence is organized into five CNS disorder macrocategories defined by shared pathophysiological processes and overlapping therapeutic targets: cerebrovascular and ischemic/hemorrhagic disorders; neurodegenerative proteinopathies and related disorders; neurotrauma and acute lesions; autoimmune, inflammatory, and emerging disorders; and retinal diseases as CNS-related sensory disorders. Although substantial preclinical evidence and encouraging early clinical signals support continued investigation, adequately powered confirmatory trials are still needed to establish whether MSC-based therapies can produce durable disease-modifying effects in neurodegenerative disorders. Translation is further limited by variability in cell sources, manufacturing procedures, doses, delivery routes, potency assays, and patient stratification by disease stage and biological phenotype. A cohesive translational roadmap should therefore combine Good Manufacturing Practice (GMP)-compliant production and mechanism-relevant potency testing with the 2025 International Society for Cell & Gene Therapy (ISCT) reporting framework. Finally, engineered MSC-EVs with modified surfaces or defined cargo may enable more targeted and controllable cell-free strategies for CNS repair.

Downloads

Published

2026-08-24

How to Cite

Krolow e Silva, S., Rondanine Sanches, I. V., Lara de Lima, J. S., & Le Sueur-Maluf, L. (2026). Mesenchymal stromal cells and paracrine modulation of neuroplasticity in the central nervous system. EXCLI Journal, 25, 1392–1419. https://doi.org/10.17179/excli2026-9599

Issue

Vol. 25 (2026)

Section

Review articles

Categories

License

Copyright (c) 2026 Sacha Krolow e Silva, Iris Virgínia Rondanine Sanches, Juliana Soares Lara de Lima, Luciana Le Sueur-Maluf

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).